NHS Cancer Blood Tests: New Trial for Adults Aged 45 and Over
The NHS is launching a major cancer blood test trial for people aged 45 and over with unexplained abdominal symptoms. Find out who may qualify and how the tests work.
Thousands of people across England could benefit from a major NHS research trial exploring new blood tests designed to identify potential signs of cancer at an earlier stage.
The trial will focus on patients aged 45 and over who visit their GP with unexplained abdominal symptoms, including persistent bloating, stomach discomfort and other ongoing digestive problems.
Known as the STRIDE-RCT trial, the initiative aims to investigate whether advanced blood testing technology can help doctors identify patients who may need further cancer investigations more quickly.
More than 20,000 NHS patients from approximately 200 GP surgeries are expected to take part. Researchers hope the findings will provide valuable evidence about whether these tests could eventually become part of routine NHS cancer detection services.
The development represents an important step towards improving early cancer diagnosis, particularly for cancers that can be difficult to identify through conventional medical assessments.
Why Is the NHS Introducing New Cancer Blood Tests?
Detecting cancer early can significantly improve treatment opportunities and patient outcomes. However, some cancers develop with symptoms that are easily mistaken for common digestive or other health problems.
Abdominal cancers are particularly challenging to identify because their early warning signs are not always obvious.
Symptoms such as persistent bloating, abdominal pain, changes in digestion and unexplained stomach discomfort may initially appear harmless. Consequently, some patients may not receive further investigations until their condition has progressed.
According to the National Institute for Health and Care Research (NIHR), approximately 71,000 people in England are diagnosed with bowel, stomach, liver, pancreatic or ovarian cancer every year. These conditions account for nearly 35,000 deaths annually.
The new NHS trial aims to explore whether blood-based testing could help GPs make more informed decisions about which patients need urgent investigations.
Rather than relying entirely on symptoms and traditional assessments, doctors may be able to use additional information from a patient's blood sample to identify potential cancer warning signs.
Who Could Be Eligible for the New NHS Cancer Blood Tests?
The STRIDE-RCT trial is designed for adults aged 45 and over who visit their GP with abdominal symptoms that require medical assessment.
People experiencing persistent bloating, unexplained stomach discomfort or other concerning abdominal problems may be considered for participation.
Eligible patients will be invited to provide one or two blood samples during routine blood testing at their GP surgery.
The programme is expected to involve thousands of NHS patients, although participation will depend on the trial's eligibility requirements and arrangements at individual GP practices.
Importantly, this does not mean that every person aged 45 or above will automatically receive the new tests.
Patients should continue to contact their GP if they experience persistent, unexplained or worsening symptoms rather than waiting for the trial to become available.
Which Types of Cancer Could the Blood Tests Detect?
One of the most promising aspects of the research is its potential to identify signals associated with several different cancers using a single blood sample.
The three testing technologies being investigated are:
- Enlighten test
- PinPoint test
- Halo test
Researchers are exploring whether these tests can help identify potential signs of seven cancer types:
- Bowel cancer
- Ovarian cancer
- Lung cancer
- Pancreatic cancer
- Liver cancer
- Bile duct cancer
- Stomach cancer
The tests use different approaches to examine biological signals that may be associated with cancer.
These include artificial intelligence (AI), tumour DNA detection and measurements of specific proteins found in the blood.
By combining these technologies, researchers hope to establish whether multiple cancer signals can be identified more effectively through one testing process.
However, it is important to understand that these tests are being evaluated through clinical research. Their inclusion in the trial does not mean they are already established diagnostic tests for all seven cancers.
How Will the New Cancer Blood Tests Work?
The testing process is designed to be relatively straightforward for participating patients.
First, a blood sample will be collected at the patient's GP surgery. The sample will then undergo analysis using the relevant testing technology.
The results will be sent back to the GP using a colour-coded system to help guide decisions about possible next steps.
The system includes three categories:
Green – Low Risk
A green result indicates a lower likelihood of cancer based on the test findings. It may help doctors rule out the need for additional cancer investigations through this particular pathway.
Amber – Average Risk
An amber result indicates an intermediate level of concern. Patients will continue through standard clinical assessment, with further investigations considered where appropriate.
Red – High Risk
A red result indicates a higher level of concern and suggests that the patient should be prioritised for further assessment or an urgent referral.
It is essential to remember that a red result does not automatically mean someone has cancer. Similarly, a green result cannot guarantee that cancer is absent.
The blood tests are intended to support clinical decisions, not replace a doctor's assessment or provide a final diagnosis.
Could These Tests Reduce Waiting Times for Cancer Diagnosis?
One of the main objectives of the STRIDE-RCT trial is to improve the way patients are assessed when they present with symptoms that could have several possible causes.
Currently, GPs often face challenges when deciding which patients need urgent specialist investigations.
Many abdominal symptoms are associated with relatively common, non-cancerous conditions. At the same time, overlooking an early cancer diagnosis can have serious consequences.
More accurate risk assessment could help doctors identify patients who need further testing sooner while potentially reducing unnecessary hospital referrals and invasive investigations for people at lower risk.
The trial will examine whether the new testing methods can improve this process and help the NHS use its diagnostic resources more effectively.
However, researchers will need to evaluate the results carefully before deciding whether the approach should be introduced more widely.
What Have Health Experts Said About the Trial?
The research has received support from the National Institute for Health and Care Research, which is helping to evaluate the potential benefits of these new diagnostic technologies.
Health Secretary Yvette Cooper has highlighted the importance of identifying cancer earlier, noting that earlier diagnosis can improve the chances of successful treatment and save lives.
Professor Peter Johnson, NHS national clinical director for cancer, has also welcomed the research.
He explained that the trial will help determine whether emerging blood testing technologies can help GPs identify the right patients for further investigations more quickly.
Cancer Research UK chief executive Michelle Mitchell has also welcomed the initiative.
She highlighted the need for better tools to help GPs navigate diagnostic uncertainty and decide which patients require additional testing.
The findings could therefore provide important evidence for future cancer detection strategies across England.
What Should You Do If You Have Persistent Abdominal Symptoms?
Although the new blood test trial offers encouraging possibilities, people should not ignore symptoms while waiting for new diagnostic services.
Persistent bloating, unexplained abdominal discomfort, changes in bowel habits, unexplained weight loss or other ongoing digestive problems should be discussed with a healthcare professional.
These symptoms do not necessarily indicate cancer and can have many different causes. However, persistent or unusual changes deserve appropriate medical attention.
If you are concerned about your symptoms, arrange an appointment with your GP. Your doctor can assess your medical history, examine your symptoms and recommend suitable investigations.
Do not assume that a normal blood test rules out cancer. No single test can identify every cancer in every patient.
The Future of Early Cancer Detection in the UK
The STRIDE-RCT trial could represent an important development in the NHS's approach to cancer diagnosis.
By examining whether advanced blood tests can identify potential signs of multiple cancers, researchers hope to establish whether these technologies can make diagnostic pathways faster and more effective.
For patients aged 45 and over experiencing unexplained abdominal symptoms, the research could eventually provide another tool to help doctors identify those who need further investigation.
Nevertheless, the results of the trial will be crucial. Researchers must establish how accurate and reliable the tests are, whether they improve patient outcomes and whether they offer practical benefits for the NHS.
If the evidence supports wider use, these technologies could help transform how certain cancers are investigated in the future.
For now, the most important message remains simple: recognise persistent symptoms, seek medical advice and do not delay speaking to your GP when something does not feel right.
Sources and References
- The Sun, published 16 November 2026.
- National Institute for Health and Care Research (NIHR): Information on the STRIDE-RCT research trial and the evaluation of cancer blood testing technologies.
- NHS England: Cancer diagnosis, referral and early detection information.
- Cancer Research UK: Information about cancer symptoms, early diagnosis and the importance of seeking medical advice.
Medical Disclaimer
This article is intended for general information and educational purposes only. It does not constitute medical advice, diagnosis or treatment. The cancer blood tests discussed are being investigated through a clinical trial and should not be considered confirmed diagnostic tools. Anyone experiencing persistent or unexplained symptoms should consult a qualified healthcare professional. Always follow advice provided by your GP or specialist.
